Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • psoriasis

    - PMLiVE

    J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis

    The drug is the first IL-23 inhibitor approved for children from the age of six

    - PMLiVE

    Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

    Approximately 125 million people globally are living with some form of psoriasis

    - PMLiVE

    FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis

    The Stelara biosimilar now offers all dosage forms and strengths of its reference product

    - PMLiVE

    J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis

    Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

    - PMLiVE

    Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis

    More than 2.5 million people in Europe are affected by the inflammatory bowel disease

    - PMLiVE

    Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

    More than 2.5 million people in Europe are living with the inflammatory bowel disease

    - PMLiVE

    Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis

    The inflammatory condition affects approximately 30% of psoriasis patients

    - PMLiVE

    Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease

    Inflammatory bowel disease is estimated to affect nearly two million people across Europe

    - PMLiVE

    LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

    Approximately 125 million people worldwide are affected by some form of the inflammatory condition

    - PMLiVE

    Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

    An estimated three million people in the US are affected by inflammatory bowel disease

    - PMLiVE

    J&J receives three CHMP recommendations for immunology and oncology indications

    Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively

    - PMLiVE

    J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial

    Inflammatory bowel disease affects almost one in every 100 people in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links